The publication in the link raises more questions than answers for the study indicated, IMO.
1. It does not disclose how many patients were used in the study. He did say it was done in "real world" time. Lol
2. The author of the study is a PharmD (a pharmacist), not an MD. This is significant because it questions whether the results were found in chart reviews of the patient's record, such as in a pharmacist reviewing records and looking for DVT's and Iclusig use in a patient vs an MD documenting specific sequelae during chemotherapy periods.
3. In addition, there is no specific time periods of the patients that were used in the study, or even disclosing other comorbidities of the patients being studied. This could be misleading because even though a patient may have developed a thrombotic episode with s lesser dose, there could have been a predisposition to it (Factor V disorder, smoker, central line placement, obesity)
4. Most important: did the researcher have any, ANY conflict of interest that may be prejudicial in the study.
